Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandemic Perspectives: Remdesivir, Favipiravir’s Eventful Journeys In India A Year On

Executive Summary

COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.

You may also be interested in...



Coronavirus Update: Gilead And Zydus Cadila Expand Drugs Available In India

Gilead outlines efforts to expand availability of remdesivir in India while offers for supplies from Russia, Uzbekistan are also on the table. Zydus Cadila has received accelerated approval in India for pegylated interferon alpha-2b in moderate COVID-19 infection in adults.

Ichnos Capital Raise Key For Glenmark, BEAT Platform A Core Value Driver

All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.

As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes

Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel